<DOC>
	<DOCNO>NCT02173548</DOCNO>
	<brief_summary>- Heart Failure Preserved Ejection Fraction ( HFpEF ) common form heart failure - Standard treatment heart failure , show less ideal result HFpEF - Evidence systemic inflammation common form heart failure , include HFpEF - The main hypothesis study systemic inflammation contributes heart failure symptom exercise limitation patient HFpEF - The main objective treat patient HFpEF evidence systemic inflammation anti-inflammatory drug target Interleukin-1 ( placebo ) determine effect cardiovascular function</brief_summary>
	<brief_title>Interleukin-1 Blockade HF With Preserved EF</brief_title>
	<detailed_description>Heart Failure Preserved Ejection Fraction ( HFpEF ) common form heart failure , characterize symptom congestion impair exercise tolerance , secondary impair left ventricular filling ( diastole ) absence significant impairment contractility ( LVEF &gt; 50 % ) significant valvular abnormality , shunt intra- extra-cavitary obstruction . The standard treatment patient heart failure effective Heart Failure Reduced Ejection Fraction ( HFrEF ) , effective HFpEF . Evidence systemic inflammation common form heart failure , include HFpEF , predict bad outcome . C reactive protein ( CRP ) prefer inflammatory biomarker use risk predictor cardiovascular disease . Patients heart failure ( HFpEF HFrEF ) elevate CRP level likely severely limited heart failure symptom , likely admit hospital heart failure , likely die cardiac cause . Preclinical study show key mediator systemic inflammation , Interleukin-1 ( IL-1 ) , impairs cardiac vascular function , may contribute pathogenesis heart failure . The main hypothesis study systemic inflammation , IL-1 particular , contribute heart failure symptom exercise limitation patient HFpEF . The main objective treat patient HFpEF evidence systemic inflammation IL-1 blocker , anakinra ( recombinant human IL-1 receptor antagonist ) ( placebo ) determine effect exercise capacity measure peak oxygen consumption maximal cardiopulmonary exercise testing .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>1 . Symptoms sign heart failure ( NYHA IIIII ) prior hospitalization heart failure 2 . Recent Imaging Study ( &lt; 12 month ) show LVEF &gt; 50 % Left Ventricular End Diastolic Volume Index ( LVEDVI ) &lt; 97ml/m2 3 . Evidence abnormal LV relaxation , filling , diastolic distensibility , diastolic stiffness show one follow a. Invasive Hemodynamic measurement i. mean Pulmonary Capillary Wedge Pressure ( mPCW ) &gt; 12 ii . Left Ventricular End Diastolic Pressure ( LVEDP ) &gt; 16 mmHg b. Tissue Doppler Echocardiogram i. E/E ' &gt; 15 ii . E/E ' 815 one following : Left Ventricular Hypertrophy ( LVH ) , Atrial fibrillation , Left Atrial Enlargement ( LAE ) , E/A &lt; 0.5 + DT ( Deceleration Time ) &gt; 280 , c. Biomarkers . Brain Natriuretic Peptide ( BNP ) &gt; 200pg/ml ( due concomitant disease pulmonary arterial hypertension , pulmonary embolism , acute renal failure , ) 4 . CRP &gt; 2.0 mg/L Age &lt; 21 Concomitant condition treatment would affect completion study interpretation study test include limited following condition : physical inability walk run treadmill angina evidence spontaneous inducible ischemia uncontrolled arterial hypertension atrial fibrillation ( arrhythmias ) moderate severe valvular heart disease chronic pulmonary disease anemia ( Hgb &lt; 10 g/dl ) Angina , uncontrolled hypertension electrocardiograph ( ECG ) change ( i.e . ischemia , arrhythmia ) limit maximum exertion cardiopulmonary exercise testing Anticipated need cardiac resynchronization therapy ( CRT ) automatedimplantable cardioverter defibrillator ( AICD ) coronary revascularization cardiac surgery Active infection include chronic infection Active cancer ( prior diagnosis cancer within past 10 year ) Recent ( &lt; 14 day ) active use immunosuppressive drug ( include limit highdose corticosteroid [ &gt; 1_mg/kg prednisone equivalent ] , Tumor Necrosis Factor ( TNF ) Î± blocker , cyclosporine ) include NonSteroidal AntiInflammatory Drugs ( NSAIDs ) corticosteroid use IV dye allergy ) Chronic autoimmune autoinflammatory disease ( include limit rheumatoid arthritis , systemic lupus erythematosus ) Neutropenia ( absolute neutrophil count &lt; 1,800/mm3 [ &lt; 1,000/mm3 AfricanAmerican patient ] ) Severe impairment renal function ( estimate glomerular filtration rate &lt; 30 ml/kg*min ) Recent plan use vaccination live attenuate virus Allergy rubber latex Allergy product derive Escherichia coli Pregnancy breastfeed Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>HFpEF</keyword>
	<keyword>diastole</keyword>
	<keyword>diastolic heart failure</keyword>
	<keyword>inflammation</keyword>
	<keyword>interleukin-1</keyword>
	<keyword>C-reactive protein</keyword>
</DOC>